MindMaze Therapeutics has announced the completion of its organisational simplification initiative, and the implementation of its CHF 8 ($9.8) million strategic equity financing with Neuro.io Group. The company’s organisational simplification initiative included the selling of substantially all remaining non-neurology legacy operations acquired through its business combination with Relief Therapeutics. The transactions included a combination of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!